Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2 Gene Mutation: early-phase trial registry
3 of 5 indexed HER2 Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
HER2 Gene Mutation: 5 US clinical trials tracked, 3 recruiting.
HER2 Gene Mutation is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Fox Chase Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition her2-gene-mutation
OPEN 3 | RECR 60% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
HER2 Gene Mutation lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2 Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2 Gene Mutation is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HER2 Gene Mutation research.
Fox Chase Cancer Center accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most HER2 Gene Mutation trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
HER2 Gene Mutation research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
NCT04620187
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06123338
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
NCT05274048
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Enliven Therapeutics
NCT05650879
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2 Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2 Gene Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2 Gene Mutation page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 HER2 Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fox Chase Cancer Center sponsors the most HER2 Gene Mutation trials on record, review their full trial history before evaluating a specific study. See Fox Chase Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2 Gene Mutation condition card totals 5 registered trials; most-linked intervention BL-M17D1; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.